Canadian Cancer Trials Group Bulletins


Recent Publications

IND.149 -- Primary Publication

Hirte H, Oza A, Swenerton K, Ellard SL, Grimshaw R, Fisher B, Tsao M, Seymour L. A phase II study of erlotinib (OSI-774) given in combination with carboplatin in patients with recurrent epithelial ovarian cancer (Canadian Cancer Trials Group IND.149). Gynecol Oncol 118: 308-12, 2010.

IND.173 -- Primary Publication

Renouf DJ, Moore MJ, Hedley D, Gill S, Jonker D, Chen E, Walde D, Goel R, Southwood B, Gauthier I, Walsh W, McIntosh L, Seymour L. A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer (ONLINE). Invest New Drugs 2010.

A Phase III Prospective Randomized Study of Adjuvant Chemotherapy with Vinorelbine and Cisplatin in Completely Resected Non-Small Cell Lung Cancer with Companion Tumour Marker Evaluation

Tsao M-S, Sakurada A, Ding K, Aviel-Ronen S, Ludkovski O, Liu N, Le Maître A, Gandara D, Johnson D, Rigas J, Seymour L, Shepherd FA. Prognostic and predictive value of epidermal growth factor receptor tyrosine kinase domain mutation status and gene copy number for adjuvant chemotherapy in non-small cell lung cancer. J Thoracic Oncol 6: 139-47, 2011.

Trial Design

Bradbury P, Hilton J, Seymour L. Early-phase oncology clinical trial design in the era of molecularly targeted therapy: pitfalls and progress. Clin Invest 1: 33-44, 2011.


Jiang S, Tu D. Empirical likelihood confidence intervals for ratio of hazard rates under right censorship. Statistics and Its Interface 4: 464, 2010.

Sun X, Peng P, Tu D. Phase II cancer clinical trials with a one-sample log-rank test and its corrections based on the Edgeworth expansion. Contemporary Clin Trials 32: 108-13, 2011.